|
| Press Releases |
|
|
| Monday, December 28, 2009 |
|
|
金山软件和盛大游戏成立合资公司 |
| 中国领先的娱乐及应用软件发展商、分销商及服务供应商(以市场占有率计)金山软件有限公司(「金山软件」或「本公司」，股份代号：03888)欣然宣布与盛大游戏发展有限公司(「盛大游戏」)已达成共同出资成立合资公司的意向。 more info >> |
|
|
金山軟件和盛大遊戲成立合資公司 |
| 中國領先的娛樂及應用軟件發展商、分銷商及服務供應商(以市場佔有率計)金山軟件有限公司(「金山軟件」或「本公司」，股份代號：03888)欣然宣佈與盛大遊戲發展有限公司(「盛大遊戲」)已達成共同出資成立合資公司的意向。 more info >> |
|
|
Kingsoft and Shanda Games to Form Joint Venture Company |
| Kingsoft Corporation Limited ("Kingsoft" or the "Company"; SEHK stock code: 03888), China"s leading entertainment and applications software developer, distributor and service provider in terms of market share, is pleased to announce that the Company and Shanda Games Limited ("Shanda Games") has agreed to form a joint venture company. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
analytica Hanoi 2026 Makes Its Debut, Bringing the Global Science and Laboratory Platform to Northern Vietnam
Feb 25, 2026 19:57 HKT/SGT
|
|
|
HKTDC welcomes the 2026-27 Budget
Feb 25, 2026 18:29: JST
|
|
|
周大福人壽支持《財政預算案》有關跨境安老、落實《香港可持續披露準則》以及推動體育普及化、盛事化等措施
Feb 25, 2026 18:07 HKT/SGT
|
|
|
HKTDC welcomes the 2026-27 Budget
Feb 25, 2026 17:29 HKT/SGT
|
|
|
NEC Implements AI Code Review Service "Metabob," Reducing Technical Verification Time by Up to 66%
Feb 25, 2026 18:00 JST
|
|
|
維昇藥業（2561.HK）維臻高(R)獲批：重長效生長激素王者登場 重構百億市場的商業天花板
Feb 25, 2026 14:58 HKT/SGT
|
|
|
Shoucheng Holdings (00697.HK) Sees Long-Term International Capital Rotation as Robotics Portfolio Enters Harvest Phase
Feb 25, 2026 12:23 HKT/SGT
|
|
|
首程控股（00697.HK）迎來國際長線接盤 機器人產業生態進入價值收割期
Feb 25, 2026 12:23 HKT/SGT
|
|
|
首程控股（00697.HK）迎来国际长线接盘 机器人产业生态进入价值收割期
Feb 25, 2026 12:23 HKT/SGT
|
|
|
ベイシアのスーパーマーケット内の冷蔵・冷凍庫の温度点検・記録業務を富士通のIoT可視化ソリューションにより自動化
Feb 25, 2026 12:00: JST
|
|
|
Beisia Automates Supermarket Refrigerator Temperature Monitoring and Recording with Fujitsu's IoT Visualization Solution
Feb 25, 2026 12:00 JST
|
|
|
國泰君安國際獲批使用SIMM 衍生品風險管理接軌國際標準
Feb 25, 2026 10:34 HKT/SGT
|
|
|
国泰君安国际获批使用SIMM 衍生品风险管理接轨国际标准
Feb 25, 2026 10:34 HKT/SGT
|
|
|
CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China
Feb 24, 2026 22:30: JST
|
|
|
CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China
Feb 24, 2026 21:30 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
